The Nutrition Society is one of the largest learned societies for nutrition in the world. In late 2019, Dr Aaron Lett led the bid to bring this student-focused conference of the Nutrition Society’s conference calendar to Imperial College London. This was the first conference the Section of Nutrition Research at Imperial has hosted and provided the perfect opportunity for Imperial to share its expertise in nutrition-related research and strong ethos and enthusiasm for student development to undergraduate and postgraduate nutrition students across the world. (more…)
On Mesothelioma Awareness Day, Dr Anca Nastase provides an insight into mesothelioma and how research advances offer new hope for improved treatment.
Mesothelioma Awareness Day represents a great opportunity to gain more information about the disease biology, risk factors or symptoms from everyone in the mesothelioma community. Raising awareness is essential as it has the potential to improve prevention and early diagnosis and can translate into better outcomes and better survival for the patients.
My aim as a scientist within the National Centre for Mesothelioma Research (NCMR) is to deepen the molecular research in mesothelioma and to advance our understanding of the mechanisms responsible for the onset and progression of this disease.
Although progress has been made in the field, further understanding of the pathophysiology is still desperately needed.
Mesothelioma is a type of cancer that arises and develops in the thin layer that covers the human internal organs, called mesothelium.
Firstly, I think it is incredible that HDRUK recognises the lack of black people within health data science and has given us, interns, the opportunity to explore this sector. Why is it important to have diversity within health data science? Increasing diversity increases the ability to fight against systemic racism and discrimination. This is an ongoing battle, and it is so important that everyone plays their part in challenging it.
During these last six weeks I, have had many experiences such as listening to various talks, working on my own projects, and meeting some amazing, knowledgeable people. (more…)
On Clinical Trials Day, Fran Husson discusses how receiving treatment for Acute Myeloblastic Leukaemia made her aware of the value and impact of research.
It is impossible, as a patient, not to think “vaccination” when asked to engage in some reflection about “Research”. Vaccines would not have been created so swiftly to combat Sars-CoV-2 if strong and well established multi-disciplinary cohorts of researchers, within prominent academic institutions, had not been in place to mastermind clinical trials and produce an effective immunisation response to the pandemic.
This begs the question of Patient and Public awareness of research, whether for clinical purposes or service delivery of health and social care. Do we need such a devastating global pandemic to raise the profile of research?
In my case, a late diagnosis of Acute Myeloblastic Leukaemia provided the lightning bolt to make me aware of research. Hospitalised in isolation for ten months, under round-the-clock treatment from clinicians who also involved me in different clinical research projects, I could not but appreciate the full value and impact of research. (more…)
NHLI researchers Róisín Mongey and Dr Sally Kim provide an insight into developing a new tool – the AIR model – for lung research and drug development.
Lung diseases represent a significant global health burden costing the NHS upwards of £1 billion annually. A hallmark of chronic and acute adult lung diseases such as Chronic Obstructive Pulmonary Disease (COPD), Idiopathic Pulmonary Fibrosis (IPF) and COVID-19, is lung damage. The lungs are usually capable of repairing damage but in some cases, this does not happen or the repair process goes awry for example going into overdrive and causing more damage. The result of this lack of repair or abnormal repair is persistent tissue damage and declining lung function.
There are almost no treatments available to repair the lung damage in these diseases. A bold, new approach to identify novel lung repair treatments for these diseases is needed. Unfortunately, there are several roadblocks to the development of curative treatments, the primary one being that we don’t fully understand how repair happens in the healthy lung under normal circumstances. The bottom line is that unless we can figure this out, it is unlikely that we will be able to develop successful new repair treatments. (more…)
Australia was the first country in the world to introduce standardised, or plain, packaging for cigarettes and tobacco. The move was the product of a long-running campaign from the public health community and meant that the packets are allowed no branding; just the product name in standard font, colour and size. Since Australia brought in these measures, the UK followed in 2017, as did Ireland and France, increasing the number of countries in the world which restrict one of the key avenues for the tobacco industry to advertise their products. (more…)
As the global COVID-19 pandemic draws on, effects are being felt by everyone, not just those who have been infected with the virus. From schools to offices, restaurants to gyms, many aspects of ‘normal’ have been closed, stopped, or undergone major adaptations. These societal and healthcare disruptions will affect people differently, with certain groups of people, such as those with respiratory conditions, potentially more vulnerable.
Over the last few months I have been working with Dr Nicholas Hopkinson (Respiratory Consultant, NHLI Academic, and Medical Director of the British Lung Foundation(BLF)), Dr Bradley Lonergan (Internal Medicine Trainee) in collaboration with the Asthma UK-BLF partnership, to try to understand how people with long term respiratory conditions have been impacted by measures to reduce the risk of COVID-19.
Our research published today in BMJ Open explores the findings of a large UK wide survey conducted at the height of the first wave. We found that measures to reduce risk of COVID-19, such as social distancing and changes to healthcare provision, were having profound impacts on people with long term respiratory conditions. These included cancellations of appointments, investigations, and vital aspects of their care such as pulmonary rehabilitation. (more…)
Dr Holly Jenkins provides an insight into her research looking at bacterial communities in the guts of preterm babies from analysing stool samples.
Every year in the UK, one in 13 babies are born prematurely. A premature birth is one that occurs before the 37th week of pregnancy. It is one of the leading causes of neonatal morbidity and mortality – that’s why research is extremely important. I decided I wanted to pursue a career in neonatal research because of the amazing clinical and scientific work that is helping improve the care and lives of babies born too soon.
From 2015 to 2018 I completed my PhD in Professor Neena Modi’s leading neonatal research team, based at Chelsea and Westminster Hospital. The team is comprised of clinicians (doctors, nurses and midwives), scientists, statisticians and data analysts, all of which are researching different aspects of preterm and term births. (more…)
Professor Danny Altmann explores how the pandemic has offered new perspectives on his research, leading to new collaborations and engaging with policy.
If any of us ever wished for greater prominence, respect, or public understanding of our scientific contributions to society, this is not the way we would have wished to achieve it. For so many at Imperial working in diverse aspects of infection, immunity and global health, this has been a time of much urgent soul-searching as to how we can best bring our skill sets to bear on the problem most effectively, whether as clinicians, disease modellers, vaccinologists or basic immunologists. It’s hard to turn on a news broadcast or open a newspaper without seeing opinions from Imperial colleagues, clinical and scientific.
At a time when the mantra is ‘policy led by the science’, this is absolutely as it should be. We often have it ingrained as scientists to keep our heads down lest we be accused of showboating or playing ‘Johnny-Big-Potato’ by making inflated claims about our research. Yet, this is a time when it’s OK and even laudable to stick your head above the parapet: when it genuinely matters, and people genuinely want to know, what are these different types of antibody tests, is antibody protective and how long does it last, which may be the most effective vaccines. This surely is the time to step up to the plate, whether by adapting the research focus of our labs to the current issues, by communicating and trying to clarify the nuances, and of course, by remembering our commitments to our students and trying to work out how to keep them stimulated and scientifically productive despite lockdown. (more…)
Kelly Gleason, CRUK Lead Nurse, explores the value of patient and public involvement in cancer research and how it can improve the quality and outcomes of research.
Patient and public involvement (PPI) is increasingly recognised as important. Funding bodies are asking for more and more from researchers in regard to patient and public involvement. They want to see evidence of authentic and ongoing relationships between researchers and the public that is informing what is being researched, how it is being researched and how findings are shared with the public. Funders want to see more co-creation between researchers and the public and for this to happen, researchers require help accessing larger patient networks and support in maintaining relationships with patients.
My journey with PPI at Imperial
I became involved in patient and public involvement almost a decade ago – it was a relatively novel concept back then. The need for cancer researchers to access patients to involve in their research was increasing. The Imperial Cancer Research UK Centre, where I work as a Lead Nurse, established a group of patients and members of the public for Imperial researchers to have easy access to the patient voice. The group served as a resource to researchers and inputted on everything from grant proposals to lay summaries. They helped us create a research culture at Imperial where patients were integral to what and how we carried out cancer research. (more…)